Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer - Takeaways - MDSpire

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

  • By

  • Mayu Watanabe

  • Jun Eguchi

  • Atsushi Takamoto

  • Jun Wada

  • June 10, 2026

  • 0 min

Share

  • 1

    HLA class II alleles were linked to shorter progression-free survival (PFS) in patients receiving immune checkpoint inhibitors (ICIs).

  • 2

    Patients with the DRB1*04:05 allele had a median PFS of 2 months, significantly shorter than the 3 months for those without this allele.

  • 3

    The study included 96 Japanese patients with advanced cancer who received at least one dose of anti-PD1 therapy.

  • 4

    DRB1*04:05 was independently associated with worse survival outcomes in ICI-treated patients, indicating a potential immunogenetic impact.

  • 5

    The findings suggest that HLA genotype may influence ICI efficacy through effects on immune regulation and pancreatic β-cell vulnerability.

Original Source(s)

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

  • by Mayu Watanabe, Jun Eguchi, Atsushi Takamoto, Jun Wada

  • June 10, 2026

Related Content

Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement

Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer

Early risk stratification and temporal biomarker patterns of trousseau syndrome-related cerebral infarction in lung cancer